Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
Abstract Introduction Analyzing longitudinal cancer quality‐of‐life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopu...
Main Authors: | Jiahui Zhang, Weili Kong, Pingzhao Hu, Derek Jonker, Malcolm Moore, Jolie Ringash, Jeremy Shapiro, John Zalcberg, John Simes, Dongsheng Tu, Chris J. O'Callaghan, Geoffrey Liu, Wei Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-03-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5341 |
Similar Items
-
Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
by: Daniel Shepshelovich, et al.
Published: (2018-11-01) -
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
by: Daniel J. Renouf, et al.
Published: (2022-08-01) -
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
by: Lyn Ley Lam, et al.
Published: (2023-02-01) -
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
by: John Hilton, et al.
Published: (2022-06-01) -
Myotonic dystrophy-2: Unusual phenotype due to a small CCTG-expansion
by: Finsterer J, et al.
Published: (2018-12-01)